Person:
YAĞÇI ÇAĞLAYIK, DİLEK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

YAĞÇI ÇAĞLAYIK

First Name

DİLEK

Name

Filters

2017 - 201912020 - 20231
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    IS CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS TOPOTYPE IMPORTANT IN THE POSSIBILITY OF NOSOCOMIAL TRANSMISSION?
    (CARBONE EDITORE, 2017) YAĞÇI ÇAĞLAYIK, DİLEK; Kuscu, Ferit; Komur, Suheyla; Caglayik, Dilek Yagci; Ulu, Aslihan; Inal, Ayse Seza; Kurtaran, Behice; Tasova, Yesim; Aksu, Hasan Salih Zeki; Ozkul, Aykut
    Introduction: Crimean-Congo hemorrhagic fever (CCHF) is a viral zoonotic disease which is mainly transmitted by tick bite. Contact with blood or body secretions of viremic humans or animals is also among the other modes of transmission. In this study, the serological states in terms of CCHF tested in healthcare workers (HCW) who had had contact with two fatal patients with a diagnosis of CCHF. The relation of the transmission possibility with the phylogenetic analysis of the virus were evaluated. Materials and methods: CCHF IgM and IgG were investigated with ELISA one month after contact with index cases in HCW. The contact levels and states of use of personal protective equipment (PPE) were evaluated. Phylogenetic analysis with sequence analysis based on partial sequences of NP coding region was performed for CCHF viruses detected in the index cases. Results: CCHF IgM and IgG were found negative in any of 20 healthcare workers some of whom had a history of high-risk contact. The sequence analysis revealed that the viruses found in both patients were identical. Phylogenetic evaluation showed that both viruses have high homology with the viruses which were determined previously in the endemic area in Turkey. Conclusion: As in our study, detection of virus topotype with sequence analysis in studies about nosocomial transmission will help to determine if there is a difference between virus subtypes in terms of transmission.
  • No Thumbnail Available
    PublicationMetadata only
    Prevalence of polypharmacy and potential drug-drug interactions associated with risk factors in the era of hiv integrase inhibitors: A prospective clinical study
    (2023-02-01) YAĞÇI ÇAĞLAYIK, DİLEK; TİGEN, ELİF; SİLİ, ULUHAN; ERTÜRK ŞENGEL, BUKET; KORTEN, VOLKAN; Altunal L. N., YAĞÇI ÇAĞLAYIK D., Ozel A. S., TİGEN E., SİLİ U., ERTÜRK ŞENGEL B., Aydin M., KORTEN V.
    People living with human immunodeficiency virus (PLWH), with the availability of modern antiretroviral drugs, have multiple comorbidities, which increase the risk of polypharmacy and potential drug-drug interactions (PDDIs). This is a particularly important issue for the aging population of PLWH. This study aims to review the prevalence and risk factors for PDDIs and polypharmacy in the era of HIV integrase inhibitors. A cross-sectional, two-center, prospective observational study was conducted on Turkish outpatients between October 2021 and April 2022. Polypharmacy was defined as the use of >= 5 non-HIV medications, excluding over-the-counter (OTC) drugs, and PDDIs were classified using the University of Liverpool HIV Drug Interaction Database (harmful/red flagged and potentially clinically relevant/amber flagged). The median age of the 502 PLWH included in the study was 42 +/- 12.4 years and 86.1% were males. Most individuals (96.4%) were given integrase-based regimens (unboosted 68.7% and boosted 27.7%). In total, 30.7% of individuals were taking at least one OTC drug. The prevalence of polypharmacy was 6.8% (9.2% when OTC drugs were included). During the study period, the prevalence of PDDIs was 1.2% for red flag PDDIs and 16% for amber flag PDDIs. CD4(+) T cell count >500 cells/mm(3), number of comorbidities >= 3, comedication with drugs affecting blood and blood-forming organs, cardiovascular drugs, and vitamin/mineral supplements were associated with red flag or amber flag PDDIs. Drug interaction prevention is still important in HIV care. Individuals with multiple comorbidities should be closely monitored for non-HIV medications to prevent PDDIs.